Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance

Petra Obioma Nnamani,1,2 Agatha Adaora Ugwu,1 Emmanuel Chinedu Ibezim,1 Franklin Chimaobi Kenechukwu,1 Paul Achile Akpa,1 John-Dike Nwabueze Ogbonna,1 Nicholas Chinedu Obitte,3 Amelia Ngozi Odo,4 Maike Windbergs,2 Claus-Michael Lehr,2,5,6 Anthony Amaechi Attama1 1Drug Delivery and Nanomedicines Res...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nnamani PO, Ugwu AA, Ibezim EC, Kenechukwu FC, Akpa PA, Ogbonna JD, Obitte NC, Odo AN, Windbergs M, Lehr CM, Attama AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	malaria artemisinin-based combination therapy antiplasmodial activity liquisolid compacts nanostructured lipid carriers Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/34fb64c51fff4e25af1ebd1797d689a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34fb64c51fff4e25af1ebd1797d689a2
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN
topic	malaria artemisinin-based combination therapy antiplasmodial activity liquisolid compacts nanostructured lipid carriers Medicine (General) R5-920
spellingShingle	malaria artemisinin-based combination therapy antiplasmodial activity liquisolid compacts nanostructured lipid carriers Medicine (General) R5-920 Nnamani PO Ugwu AA Ibezim EC Kenechukwu FC Akpa PA Ogbonna JD Obitte NC Odo AN Windbergs M Lehr CM Attama AA Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
description	Petra Obioma Nnamani,1,2 Agatha Adaora Ugwu,1 Emmanuel Chinedu Ibezim,1 Franklin Chimaobi Kenechukwu,1 Paul Achile Akpa,1 John-Dike Nwabueze Ogbonna,1 Nicholas Chinedu Obitte,3 Amelia Ngozi Odo,4 Maike Windbergs,2 Claus-Michael Lehr,2,5,6 Anthony Amaechi Attama1 1Drug Delivery and Nanomedicines Research Group, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria; 2Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University, Saarbrücken, Germany; 3Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, 4Department of Human Kinetics and Health Education, University of Nigeria, Nsukka, Nigeria; 5PharmBioTec GmbH, 6Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, Germany Abstract: The present study aimed to develop low-dose liquisolid tablets of two antimalarial drugs artemether–lumefantrine (AL) from a nanostructured lipid carrier (NLC) of lumefantrine (LUM) and estimate the potential of AL as an oral delivery system in malariogenic Wistar mice. LUM-NLCs were prepared by hot homogenization using Precirol® ATO 5/Transcutol® HP and tallow fat/Transcutol® HP optimized systems containing 3:1 ratios of the lipids, respectively, as the matrices. LUM-NLC characteristics, including morphology, particle size, zeta potential, encapsulation efficiency, yield, pH-dependent stability, and interaction studies, were investigated. Optimized LUM-NLCs were mixed with artemether powder and other dry ingredients and the resultant powder evaluated for micromeritics. Subsequent AL liquisolid tablets were tested for in vitro drug release and in vivo antiplasmodial activity in mice infected with Plasmodium berghei berghei (NK 65). Results showed that optimized LUM-NLC were stable, spherical, polydispersed but nanometric. Percentage yield and encapsulation efficiency were ~92% and 93% for Precirol® ATO 5/Transcutol® HP batch, then 81% and 95% for tallow fat/Transcutol® HP batch while LUM was amorphous in NLC matrix. In vitro AL release from liquisolid compacts revealed initial burst release and subsequent sustained release. Liquisolid tablet compacts formulated with Precirol® ATO 5/Transcutol® HP-AL4 achieved higher LUM release in simulated intestinal fluid (84.32%) than tallow fat/Transcutol® HP-BL3 (77.9%). Non-Fickian (anomalous) diffusion and super case II transport were the predominant mechanisms of drug release. Equal parasitemia reduction was observed for both batches of tablet compacts (~92%), superior to the reduction obtained with commercial antimalarial formulations: Coartem® tablets (86%) and chloroquine phosphate tablets (66%). No significant difference (P<0.05) in parasite reduction between double (4/24 mg/kg) and single (2/12 mg/kg) strength doses of AL compacts was observed. Our result highlights that AL could be formulated in much lower doses (4/24 mg/kg), for once-in-two days oral administration to improve patient compliance, which is currently not obtainable with conventional AL dosage forms. Keywords: malaria, artemisinin-based combination therapy, antiplasmodial activity, liquisolid compacts, nanostructured lipid carriers
format	article
author	Nnamani PO Ugwu AA Ibezim EC Kenechukwu FC Akpa PA Ogbonna JD Obitte NC Odo AN Windbergs M Lehr CM Attama AA
author_facet	Nnamani PO Ugwu AA Ibezim EC Kenechukwu FC Akpa PA Ogbonna JD Obitte NC Odo AN Windbergs M Lehr CM Attama AA
author_sort	Nnamani PO
title	Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
title_short	Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
title_full	Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
title_fullStr	Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
title_full_unstemmed	Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
title_sort	sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/34fb64c51fff4e25af1ebd1797d689a2
work_keys_str_mv	AT nnamanipo sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT ugwuaa sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT ibezimec sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT kenechukwufc sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT akpapa sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT ogbonnajd sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT obittenc sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT odoan sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT windbergsm sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT lehrcm sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance AT attamaaa sustainedreleaseliquisolidcompacttabletscontainingartemetherlumefantrineasalternatedayregimenformalariatreatmenttoimprovepatientcompliance
_version_	1718399212898484224
spelling	oai:doaj.org-article:34fb64c51fff4e25af1ebd1797d689a22021-12-02T07:43:10ZSustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance1178-2013https://doaj.org/article/34fb64c51fff4e25af1ebd1797d689a22016-11-01T00:00:00Zhttps://www.dovepress.com/sustained-release-liquisolid-compact-tablets-containing-artemether-lum-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Petra Obioma Nnamani,1,2 Agatha Adaora Ugwu,1 Emmanuel Chinedu Ibezim,1 Franklin Chimaobi Kenechukwu,1 Paul Achile Akpa,1 John-Dike Nwabueze Ogbonna,1 Nicholas Chinedu Obitte,3 Amelia Ngozi Odo,4 Maike Windbergs,2 Claus-Michael Lehr,2,5,6 Anthony Amaechi Attama1 1Drug Delivery and Nanomedicines Research Group, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria; 2Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University, Saarbrücken, Germany; 3Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, 4Department of Human Kinetics and Health Education, University of Nigeria, Nsukka, Nigeria; 5PharmBioTec GmbH, 6Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, Germany Abstract: The present study aimed to develop low-dose liquisolid tablets of two antimalarial drugs artemether–lumefantrine (AL) from a nanostructured lipid carrier (NLC) of lumefantrine (LUM) and estimate the potential of AL as an oral delivery system in malariogenic Wistar mice. LUM-NLCs were prepared by hot homogenization using Precirol® ATO 5/Transcutol® HP and tallow fat/Transcutol® HP optimized systems containing 3:1 ratios of the lipids, respectively, as the matrices. LUM-NLC characteristics, including morphology, particle size, zeta potential, encapsulation efficiency, yield, pH-dependent stability, and interaction studies, were investigated. Optimized LUM-NLCs were mixed with artemether powder and other dry ingredients and the resultant powder evaluated for micromeritics. Subsequent AL liquisolid tablets were tested for in vitro drug release and in vivo antiplasmodial activity in mice infected with Plasmodium berghei berghei (NK 65). Results showed that optimized LUM-NLC were stable, spherical, polydispersed but nanometric. Percentage yield and encapsulation efficiency were ~92% and 93% for Precirol® ATO 5/Transcutol® HP batch, then 81% and 95% for tallow fat/Transcutol® HP batch while LUM was amorphous in NLC matrix. In vitro AL release from liquisolid compacts revealed initial burst release and subsequent sustained release. Liquisolid tablet compacts formulated with Precirol® ATO 5/Transcutol® HP-AL4 achieved higher LUM release in simulated intestinal fluid (84.32%) than tallow fat/Transcutol® HP-BL3 (77.9%). Non-Fickian (anomalous) diffusion and super case II transport were the predominant mechanisms of drug release. Equal parasitemia reduction was observed for both batches of tablet compacts (~92%), superior to the reduction obtained with commercial antimalarial formulations: Coartem® tablets (86%) and chloroquine phosphate tablets (66%). No significant difference (P<0.05) in parasite reduction between double (4/24 mg/kg) and single (2/12 mg/kg) strength doses of AL compacts was observed. Our result highlights that AL could be formulated in much lower doses (4/24 mg/kg), for once-in-two days oral administration to improve patient compliance, which is currently not obtainable with conventional AL dosage forms. Keywords: malaria, artemisinin-based combination therapy, antiplasmodial activity, liquisolid compacts, nanostructured lipid carriersNnamani POUgwu AAIbezim ECKenechukwu FCAkpa PAOgbonna JDObitte NCOdo ANWindbergs MLehr CMAttama AADove Medical Pressarticlemalariaartemisinin-based combination therapyantiplasmodial activityliquisolid compactsnanostructured lipid carriersMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 6365-6378 (2016)

Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance

Ejemplares similares